Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Non-Current Liabilities: 2021-2025

Historic Total Non-Current Liabilities for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $162.4 million.

  • Kiniksa Pharmaceuticals International's Total Non-Current Liabilities rose 39.62% to $162.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.4 million, marking a year-over-year increase of 39.62%. This contributed to the annual value of $140.3 million for FY2024, which is 63.85% up from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Total Non-Current Liabilities is $162.4 million, which was up 3.53% from $156.9 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Total Non-Current Liabilities' 5-year high stood at $162.4 million during Q3 2025, with a 5-year trough of $37.9 million in Q3 2021.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $105.4 million (2024), whereas its average is $107.9 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 95.45% in 2022, then fell by 21.05% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Total Non-Current Liabilities (Quarterly) stood at $47.5 million in 2021, then grew by 29.88% to $61.7 million in 2022, then spiked by 38.81% to $85.6 million in 2023, then surged by 63.85% to $140.3 million in 2024, then surged by 39.62% to $162.4 million in 2025.
  • Its Total Non-Current Liabilities stands at $162.4 million for Q3 2025, versus $156.9 million for Q2 2025 and $136.7 million for Q1 2025.